title: Transradial approach and subclavian wired temporary pacemaker to increase safety of alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: the TRASA trial.
abstract: BACKGROUND
  Alcohol septal ablation (ASA) is a therapeutic catheter-based option and an alternative to surgical myectomy in the treatment of patients with hypertrophic obstructive cardiomyopathy. Although the safety of the ASA procedure has been consistently improved, a temporary transvenous pacemaker is recommended for at least 48h postprocedure, with several drawbacks, including the risk of cardiac perforation and infection, and the absence of any fixation mechanism. In addition, femoral artery catheterization has resulted in a concomitant increase in bleedings and iatrogenic femoral artery injuries.
  
  
  OBJECTIVE
  To evaluate and validate the feasibility of less invasive management of ASA using the transradial approach and a subclavian wired temporary pacemaker.
  
  
  METHODS
  To avoid transfemoral temporary pacing, we used a subclavian bipolar active-fixation permanent pacing lead, stitched to the skin and connected to a desterilized recuperation pacemaker. The day before discharge, if there was no high-degree atrioventricular block, the pacemaker lead was removed. In all patients, we used the right radial access and the left main was cannulated with a 6F Judkins left 3.5 guiding catheter.
  
  
  RESULTS
  Thirty consecutive patients were prospectively and successfully included in our study. No complication was observed during the hospital stay, neither access-site nor stimulation-lead related.
  
  
  CONCLUSIONS
  Our study shows the feasibility and safety of a transradial approach and a subclavian wired temporary pacemaker. The reduction in periprocedural complications offered by this strategy reflects the less invasive nature of ASA, without increasing the cost and complexity of the procedure.
authors.affiliation: Département de cardiologie, CHU de la Timone, Marseille, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Cuisset
authors.forename: Frederic
authors.initials: F
authors.lastname: Franceschi
authors.forename: Sébastien
authors.initials: S
authors.lastname: Prevot
authors.forename: Sébastien
authors.initials: S
authors.lastname: Ansaldi
authors.forename: Gilbert
authors.initials: G
authors.lastname: Habib
authors.forename: Mathieu
authors.initials: M
authors.lastname: Pankert
authors.forename: Laurent
authors.initials: L
authors.lastname: Fourcade
authors.forename: Raphael
authors.initials: R
authors.lastname: Poyet
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Bonnet
authors.forename: Jacques
authors.initials: J
authors.lastname: Quilici
mesh_terms: D055011:Ablation Techniques / Q000009:adverse effects; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control; D006328:Cardiac Catheterization / Q000009:adverse effects; D002304:Cardiac Pacing, Artificial / Q000009:adverse effects / Q000379:methods*; D002312:Cardiomyopathy, Hypertrophic / Q000628:therapy*; D000431:Ethanol / Q000008:administration & dosage* / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects; D011446:Prospective Studies; D017534:Radial Artery; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000431:Ethanol